Cargando…
Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation
Endostar, a novel recombinant human endostatin, which was approved by the Chinese State Food and Drug Administration in 2005, has a broad spectrum of activity against solid tumors. In this study, we aimed to determine whether the anticancer effect of Endostar is increased by using a nanocarrier syst...
Autores principales: | Hu, Sanyuan, Zhang, Yangde |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000203/ https://www.ncbi.nlm.nih.gov/pubmed/21170352 http://dx.doi.org/10.2147/IJN.S14753 |
Ejemplares similares
-
Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers
por: Chen, Weijie, et al.
Publicado: (2011) -
Applications of daunorubicin-loaded PLGA-PLL-PEG-Tf nanoparticles in hematologic malignancies: an in vitro and in vivo evaluation
por: Bao, Wen, et al.
Publicado: (2019) -
Docetaxel Loaded PEG-PLGA Nanoparticles: Optimized Drug Loading, In-vitro Cytotoxicity and In-vivo Antitumor Effect
por: Noori Koopaei, Mona, et al.
Publicado: (2014) -
Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo
por: Duan, Dongyu, et al.
Publicado: (2018) -
Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles
por: Fodor-Kardos, Andrea, et al.
Publicado: (2020)